ライフサイエンスコーパス: specific therapy

1 r to the usual-care group (which received no specific therapy).

2 patients who have not received prior disease-specific therapy.

3 select patients most likely to respond to a specific therapy.

4 prompted us to consider organ-targeted, cell-specific therapy.

5 therapeutics with half-lives adapted to the specific therapy.

6 cytial virus (RSV) infections remain without specific therapy.

7 we make a strong recommendation against PAH-specific therapy.

8 ation of any consistently effective, patient-specific therapy.

9 otype infecting strains and utilize serotype-specific therapy.

10 s counselling and encourages early, syndrome-specific therapy.

11 ence of PNH at presentation will require PNH-specific therapy.

12 last major lipoprotein disorder without any specific therapy.

13 hal complication of severe sepsis that lacks specific therapy.

14 f finasteride, the rash resolved without any specific therapy.

15 in industrially developed countries and lack specific therapy.

16 morbidity and mortality, but currently lack specific therapy.

17 is and facilitate the development of antigen-specific therapy.

18 treated and which should be monitored on no specific therapy.

19 ents with either type of PH who received PAH-specific therapy.

20 candidates in whom AKI does not resolve with specific therapy.

21 s, to quantify disease activity and to guide specific therapy.

22 rate diagnosis and more-timely initiation of specific therapy.

23 nked to clinical events, and the efficacy of specific therapy.

24 of cells, which could be explored for tumor-specific therapy.

25 which can result in variable responses to a specific therapy.

26 nges associated with manufacturing a patient-specific therapy.

27 risk, and in some cases to provide genotype-specific therapy.

28 o a significant delay in diagnosis and Fabry-specific therapy.

29 marker for ovarian CSCs and a target for CSC-specific therapy.

30 each allele might be exploitable for allele-specific therapy.

31 ical evidence of a predictive benefit from a specific therapy.

32 luded phenotyping is essential for phenotype-specific therapy.

33 s will be important in development of gender-specific therapies.

34 ia promotes the resistance of tumor cells to specific therapies.

35 whose solution underlies the development of specific therapies.

36 s are most likely to benefit or be harmed by specific therapies.

37 nd replaced with recommendations tailored to specific therapies.

38 ic incentives to catalyse the development of specific therapies.

39 ngestion, and whether patients are receiving specific therapies.

40 hase, in patients with PAH refractory to PAH-specific therapies.

41 of TB-IRIS and may assist the development of specific therapies.

42 utations could lead to personalized mutation-specific therapies.

43 esents a potential target for tumor vascular-specific therapies.

44 progression, and they can guide in tailoring specific therapies.

45 n of the disease, paving the way for subtype-specific therapies.

46 ys as potential targets for cancer stem cell-specific therapies.

47 ng diagnostic markers and targets for cancer-specific therapies.

48 ory failure, which has high mortality and no specific therapies.

49 ilitate the development of advanced mutation-specific therapies.

50 se diagnosis and more effective and pathogen-specific therapies.

51 tients with an HRD phenotype may help tailor specific therapies.

52 d candidates for different types of mutation-specific therapies.

53 healthcare environment and most received PH-specific therapies.

54 er properties may lead to more effective and specific therapies.

55 e development of novel stem cell and disease-specific therapies.

56 ractices and differential leukemogenicity of specific therapies.

57 ies of disease mechanisms and for developing specific therapies.

58 standardized, and there are no validated PCD-specific therapies.

59 presents an attractive target to develop CSC-specific therapies.

60 sk solid tumors, urgently need effective and specific therapies.

61 % of renal transplants per annum, and eludes specific therapies.

62 uss the possibility of developing aneuploidy-specific therapies.

63 low and high EUTOS score, overall and within specific therapies.

64 iology of AKI may lead to the development of specific therapies.

65 sis, prognosis, or prediction of response to specific therapies.

66 use this information to develop vascular bed-specific therapies.

67 ems that may be used to identify new subtype specific therapies.

68 ovide targets for the development of disease-specific therapies.

69 utoimmune diseases, and development of cause-specific therapies.

70 et of dSSc patients who could be targeted by specific therapies.

71 patients are likely to benefit from disease-specific therapies.

72 pecific nature of TAO and the development of specific therapies.

73 poor prognosis and may influence response to specific therapies.

74 diagnoses in the ICU, and important alcohol-specific therapies.

75 DCM, which limits the potential for disease-specific therapies.

76 enic pathways, and encourage innovative site-specific therapies.

77 le targets for individualized EBV and cancer-specific therapies.

78 rapies and the opportunities to develop more specific therapies.

79 avenues for the future development of strain-specific therapies.

80 including those who were not treated with PH-specific therapies.

81 hich mainly depend on underlying disease and specific therapies.

82 e differential responsiveness of patients to specific therapies.

83 s for the development of stromal compartment-specific therapies.

84 vidual pediatric endotypes might require age-specific therapies.

85 nically distinct subgroups that benefit from specific therapies.

86 ghts that can be rapidly translated into CSC-specific therapies.

87 s in opioid abuse patterns and may guide sex-specific therapies.

88 t roles for EGFR in the response to oncogene-specific therapies.

89 t than immunocompromised did not receive any specific therapy (25.5% vs. 4.4%, p <= 0.01).

90 Thirty-five patients received specific therapy against cryptosporidiosis ie nitozoxani

91 others patients had neither IS reduction nor specific therapy against cryptosporidiosis.

92 ents that could ultimately be used to target specific therapy against these antibodies, we characteri

93 rlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein

94 jor risk factor for kidney stones and has no specific therapy, although Oxalobacter formigenes coloni

95 ets and as biomarkers to select patients for specific therapies and their combinations.

96 scular disease and in the design of vascular-specific therapies and tissue engineering.

97 mplex diseases (that can then be targeted by specific therapies) and drug repurposing.

98 s of patients with optimal responses to more specific therapies, and development of biomarkers that i

99 Treatment of PoPH includes PAH-specific therapies, and in certain cases, such therapies

100 ual management plans, assessing criteria for specific therapies, and predicting outcomes.

101 There is currently no specific therapy, and our ability to predict who will de

102 r hypertrophy (LVH), eligibility for disease-specific therapy, and prognosis.

103 Currently, no NASH-specific therapies are approved by the US Food and Drug

104 No specific therapies are available for these abnormalities

105 Antigen-specific therapies are in their infancy, but the latest

106 al loss during pregnancy remains obscure and specific therapies are lacking.

107 ilable), identifying patient subsets in whom specific therapies are likely to be effective or ineffec

108 s have improved with better supportive care, specific therapies are limited.

109 Migraine-specific therapies are now approved for the acute treatm

110 Disease-specific therapies are reviewed.

111 with systolic dysfunction, for whom most HF-specific therapies are targeted.

112 Specific therapies are unavailable.

113 auses of transfusion-related fatalities, and specific therapies are unavailable.

114 virus disease 2019 (COVID-19), efficient and specific therapies are urgently needed.

115 Although preventive vaccination and specific therapies are yet to be developed, exploring th

116 udes establishing a diagnosis for diagnostic-specific therapies as well as preventive strategies for

117 ress toward clinical implementation of HMGB1-specific therapy as a means to treat APAP-ALI and other

118 iorgan system failure, and to tailor disease-specific therapy as early as possible in the disease pro

119 to clarify the role of INCS sprays as asthma-specific therapy, as well as the role of the nasal inhal

120 There are no specific therapies available to protect individuals from

121 or complication of diabetes mellitus with no specific therapy available to date.

122 de avoidance, there is currently no allergen-specific therapy available.

123 Specific therapies based on knowledge of viral functions

124 d use of the results of such tests to direct specific therapies based on laboratory hypotheses, but w

125 Eligibility for disease-specific therapy based on MWT was discordant between mod

126 is imaging-derived information, the need for specific therapies besides optimised medical therapy can

127 ion in the development of leukemia stem cell-specific therapy by targeting SALL4.

128 number of older patients, and outcomes after specific therapies can be different depending on age.

129 or oncogenic target identification such that specific therapies can be matched with individual patien

130 ardial dilation, a disease phenotype lacking specific therapies, can be prevented by targeted replace

131 Cutting edge brain-specific therapies, capable of circumventing the physica

132 These disease-specific therapies combined with novel therapies to acce

133 or patients who received assay-directed site-specific therapy compares favorably with previous result

134 ilored" or "personalized" medicine, in which specific therapies could be prescribed based on a patien

135 within the broad spectrum of COPD, targeted specific therapies could improve disease management.

136 ry tumour and development of a tailored site-specific therapy could improve the survival of these pat

137 ets for treating ALI, for which there are no specific therapies currently available.

138 se genetic data have implications for allele-specific therapy currently being developed for PXE.

139 testinal reasons for hospitalization with no specific therapy currently.

140 l resuscitation (CCR) represents a bundle of specific therapies designed to enhance perfusion during

141 ific risks, the potential application of sex-specific therapy designed to avoid poor long-term advers

142 Given pathophysiology of stroke, site-specific therapy directed at left atrial appendage occlu

143 g additional pulmonary arterial hypertension-specific therapy discontinued study treatment; survival

144 ic immunotherapy, vaccines, and non-allergen-specific therapies (eg, monoclonal antibodies) are being

145 n about chronic disease pathogenesis, and no specific therapies exist for acute or chronic CHIKV dise

146 ll potential commercial market, few, if any, specific therapies exist for these conditions.

147 rms of cardiomyopathy, and no proven disease-specific therapies exist yet.

148 orly understood, and no approved vaccines or specific therapies exist.

149 of toxicity is only partially known, and no specific therapy exists for sulfide poisoning.

150 cific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) con

151 l weapons against dangerous viruses where no specific therapy exists, as in the case of the ongoing S

152 C3G) is a severe kidney disease for which no specific therapy exists.

153 Currently, there are no specific therapies for AML1-ETO-positive AML.

154 or receptor (CD74) may provide new, targeted specific therapies for androgen-independent prostate can

155 may have therapeutic applications as target-specific therapies for cancer.

156 These results will help to develop mutation-specific therapies for children and adults suffering fro

157 ucture, but also suggest that development of specific therapies for CRPC should take account of targe

158 As there are no specific therapies for JEB, we tested whether a protein

159 TM function or may be exploited by designing specific therapies for MCL cases with p53 aberrations.

160 These results thus support a role for T cell-specific therapies for myocarditis.

161 nergy sensing and energy balance may lead to specific therapies for obesity and diabetes and for thei

162 ng is the next challenge, to enable genotype-specific therapies for patients with AML and other malig

163 ed treatments and the development of disease-specific therapies for pediatric cardiomyopathies are in

164 s current pathophysiologic understanding and specific therapies for PI3K pathway defects leading to i

165 There are currently no specific therapies for STEC-associated HUS, and the mech

166 Specific therapies for symptomatic patient types are mor

167 301L mutant, indicating the need for disease-specific therapies for tauopathies.

168 s on development of safer antipsychotics and specific therapies for the different tardive syndromes a

169 findings might help to develop novel antigen-specific therapies for the treatment of allergy and auto

170 ay could facilitate the development of novel specific therapies for the treatment of painful PDN.

171 ir known or suspected infections and without specific therapies for their glomerulonephritis, includi

172 cial reward and in the development of gender-specific therapies for these disorders.

173 afferents that could be exploited to design specific therapies for visceral hypersensitivity.

174 o-called "augmentation therapy"-represents a specific therapy for AAT deficiency and raises serum lev

175 presents an important step toward an antigen-specific therapy for anti-MAG neuropathy.

176 No specific therapy for any human coronavirus is available,

177 and support translation of PMT as the first specific therapy for children with hPAP.

178 to HSC, potentially allowing tailored, cell-specific therapy for HCC.

179 There is no specific therapy for HS.

180 venous AAT (alpha-1 antitrypsin) is the only specific therapy for individuals with pulmonary disease

181 teriophages (phages) is proposed as a highly specific therapy for intestinal pathobiont elimination.

182 There is no specific therapy for LMNA-associated cardiomyopathy.

183 immunogenic DCs can be engineered for myelin-specific therapy for MS.

184 nly biomarker established for selection of a specific therapy for patients with advanced gastroesopha

185 used tumor profiling results to direct site-specific therapy for patients with CUP.

186 Even though a specific therapy for SMA is not currently available, a n

187 lass II chimera aimed at devising an antigen-specific therapy for suppression of anti-islet T cell re

188 Currently there is no approved vaccine or specific therapy for the disease.

189 The lack of specific therapy for the GSDs has driven efforts to deve

190 nt implications for the development of an Ag-specific therapy for type 1 diabetes patients.

191 recommendation could be made for or against specific therapy for uveal melanoma.

192 At present, there is no specific therapy for VLS.

193 been some of the earliest targets for tumor-specific therapy, for example, the estrogen receptor in

194 worldwide, but until recently, few migraine-specific therapies had been developed.

195 Yet to date, no eIF4E-specific therapy has been developed.

196 However, no specific therapy has been suggested to ameliorate the ne

197 ully determined to the point where mechanism-specific therapies have been developed.

198 treatment, yet the mechanisms of response to specific therapies have been largely unexplored in vivo.

199 breast cancer is a heterogeneous disease and specific therapies have not been available for a long ti

200 No specific therapies have shown any clinical benefits in p

201 Based on the unique TME for achieving tumor-specific therapy, here a novel concept of photothermal-e

202 adult studies provide the basis for most PAH-specific therapies; however, many of these medications a

203 es using the PEC-rtTA mouse may lead to more specific therapies in AKI.

204 However, clinical translation of antigen-specific therapies in general is hampered by the lack of

205 cancer and permits cell-surface targeting of specific therapies in preclinical and clinical studies o

206 w this could lead to the development of more specific therapies in the future.

207 ergic asthma that might help to develop more specific therapies in the future.

208 d that vitamin E may be considered as a NASH-specific therapy in children, and there are several ongo

209 Demonstration of efficacious antigen-specific therapy in multiple sclerosis.

210 resulted in an unmet clinical need for cell-specific therapy in the treatment of FSGS and other prot

211 s are needed to characterize responses to PH-specific therapy in this subset of patients with SAPH.

212 and has implications for the use of antigen-specific therapy in tolerance induction.

213 refining diagnoses and matching patients to specific therapies, in some cases with dramatic response

214 ferentiation-state transitions that underlie specific therapy-induced changes in differentiation-stat

215 In this study, we developed an antigen-specific therapy, insulin-coupled antigen-presenting cel

216 risk of complications associated with device-specific therapies is also an important component of the

217 No specific therapy is available, and care is generally sup

218 centage of DCMs remains unknown, and no gene-specific therapy is available.

219 genesis of CIP is not well understood and no specific therapy is available.

220 thophysiology is incompletely understood and specific therapy is lacking.

221 Specific therapy is not available for hantavirus cardiop

222 The ability to predict response to a specific therapy is particularly important for medicatio

223 Pathway-specific therapy is the future of cancer management.

224 ors involved in control of WNV infection, no specific therapy is yet available.

225 for depression, and the development of more specific therapies, is limited by the complexity of the

226 Use of PH-specific therapy may be helpful in selected patients wit

227 Q1347H, and R1314W), suggesting that allele-specific therapy may be useful for selected patients wit

228 In this regard, myelin-specific therapy may provide the desired specificity and

229 isabilities after treatment, therefore, more specific therapies need to be developed.

230 No specific therapies nor vaccine have been developed to da

231 Conclusion: Specific therapies of AKI depend on the most likely caus

232 treatment as a promising strategy for allele-specific therapy of ABCC6-associated calcification disor

233 A vaccination may offer a new approach to Ag-specific therapy of uveitis.

234 mergence is a potential threat, there are no specific therapies or licensed vaccine.

235 fy high-risk children who might benefit from specific therapies or secondary prevention interventions

236 No specific therapies or vaccines are available for LACV or

237 t may identify patients likely to respond to specific therapy or having a high probability of relapse

238 Currently, no specific therapy or treatment is available to improve pl

239 disease in humans globally, and currently no specific therapy or vaccine is available.

240 Due to the lack of disease-specific therapies, perioperative management is preventi

241 We have recently developed a cancer-specific therapy, photoimmunotherapy, which uses an anti

242 patient subgroups, selection of patients for specific therapies, prediction of risk for toxicities to

243 ction was confirmed based on the response to specific therapy regardless of culture results.

244 the appropriate place of these new migraine-specific therapies relative to other available acute and

245 What specific therapy should be instituted and which are the

246 EPICUP diagnoses who received a tumour type-specific therapy showed improved overall survival compar

247 ment of invasive therapies and novel disease-specific therapies, strategies for patient enrichment in

248 his is critically important when deciding on specific therapies such as corticosteroids or when inter

249 troke studies, especially those using region-specific therapies, such as transcranial magnetic stimul

250 As a result, more specific therapies tailored toward prognostic subgroups

251 ups of GBM with the hope of developing tumor specific therapies targeted to the unique biology within

252 recluded in vivo proof-of-concept studies of specific therapies targeting IgA1.

253 ings stimulate further exploration of region-specific therapies targeting myocytes and autonomic modu

254 es should investigate diagnostic- and gender-specific therapies targeting the neural systems implicat

255 provide a foundation for developing a cancer-specific therapy targeting BMI1.

256 preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver

257 In addition, we summarize effective specific therapies tested across major autoimmune diseas

258 profiles had better response to colon cancer-specific therapies than they did to empiric CUP therapy

259 ics are increasingly complemented by pathway-specific therapies that aim to correct the consequences

260 umor biology but also for the development of specific therapies that effectively target these cells i

261 h implications for prognosis and response to specific therapies that may provide insight into mechani

262 ratification and for the development of gene-specific therapies that may reduce the risk of life-thre

263 of IHD and may aid in the development of sex-specific therapies that reduce myocardial injury.

264 There are few specific therapies that reverse neutrophilic inflammatio

265 ized transcriptionally, and used to identify specific therapies that were validated in vivo.

266 ause early diagnosis may lead to instituting specific therapy that may prolong survival, improve qual

267 There is no specific therapy that reduces organ injury/dysfunction.

268 tudy, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence

269 enesis can be helpful for the development of specific therapies to counteract DS in a timely manner.

270 eneous and may limit the effectiveness of Ag-specific therapies to distinct disease endotypes.

271 As a result, specific therapies to halt or even reverse fibrosis have

272 fying the probable cause of DCM helps tailor specific therapies to improve prognosis.

273 ication and assignment of molecular, disease-specific therapies to improve the care of patients with

274 A major goal of cancer research is to match specific therapies to molecular targets in cancer.

275 ations for the use and monitoring of insulin-specific therapies to prevent diabetes onset.

276 ; this will allow for the rational design of specific therapies to prevent or ameliorate this serious

277 Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV)

278 There are no specific therapies to reduce mortality related to either

279 e multivariable associations may help target specific therapies to those at the greatest risk of sudd

280 To date, there are no antiviral drugs or specific therapies to treat MERS-CoV.

281 t cause is performed so that, when possible, specific therapies to treat the underlying cause can be

282 s resulted in the advance of the first eIF4E-specific therapy to clinical trials.

283 techniques may allow development of patient-specific therapy to improve outcome in patients with gli

284 autoantigen illustrates the requirement for specific therapy to induce dominant forms of tolerance,

285 ablishing more accurate diagnoses, directing specific therapy to patients who will most benefit from

286 ic perturbations are recognized as requiring specific therapy to reduce complications (such as for an

287 This study documents the first specific therapy, to our knowledge, for lowering apo(a)/

288 When stratified by specific therapy, treatment failures increased consisten

289 f GPs treated at least one patient with site-specific therapy using chemotherapeutic agents.

290 he chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib

291 e needed to determine the appropriateness of specific therapy when B cells and/or plasma cells are fo

292 d identification of patients needing anthrax-specific therapies will improve patient outcomes and res

293 r cancer therapies, as well as novel subtype-specific therapies, will be of interest.

294 ight eventually offer the potential to match specific therapies with individual patients based on a f

295 cer is a prerequisite to ultimately matching specific therapies with individual patients.

296 he development of optogenetically based cell-specific therapies with which to treat neurological dise

297 This highly efficient antigen-specific therapy with a complete avoidance of immunosupp

298 These studies identify a strategy for tumor-specific therapy with CAR-modified T cells after allo-HS

299 Specific therapy with somatostatin analogues (octreotide

300 genetically diverse disorder, such that gene-specific therapies would be practical in a small fractio